---
title: "NBIX.US (NBIX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NBIX.US/news.md"
symbol: "NBIX.US"
name: "NBIX.US"
parent: "https://longbridge.com/en/quote/NBIX.US.md"
datetime: "2026-05-21T01:56:29.485Z"
locales:
  - [en](https://longbridge.com/en/quote/NBIX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NBIX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NBIX.US/news.md)
---

# NBIX.US (NBIX.US) — Related News

### [Neurocrine Biosciences (NBIX) Valuation Check As New INGREZZA Real World Data Draws Fresh Attention](https://longbridge.com/en/news/287134643.md)
*2026-05-21T00:28:27.000Z*
> Neurocrine Biosciences (NBIX) is gaining attention due to new real-world data on INGREZZA, showing improvements in tardi

### [Neurocrine’s New Tardive Dyskinesia Trial Adds Fresh Optionality for NBIX Investors](https://longbridge.com/en/news/286946226.md)
*2026-05-19T16:32:30.000Z*
> Neurocrine Biosciences (NBIX) is conducting a Phase 2 clinical trial for its drug NBI-1065890 aimed at treating tardive 

### [Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal](https://longbridge.com/en/news/286873474.md)
*2026-05-19T07:50:30.000Z*
> Neurocrine Biosciences, Inc. presented new findings on INGREZZA's impact on mild tardive dyskinesia at the APA 2026 meet

### [Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules | NBIX Stock News](https://longbridge.com/en/news/286813263.md)
*2026-05-18T12:05:29.000Z*
> Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and I

### [Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics | NBIX Stock News](https://longbridge.com/en/news/286773551.md)
*2026-05-18T04:50:26.000Z*
> Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics | NBIX Stock News

### [Gohigh News - Factset's latest survey: Neurocrine Biosciences (NBIX-US) EPS estimate revised up to 6.8 yuan, estimated target price is 186.00 yuan](https://longbridge.com/en/news/285376238.md)
*2026-05-06T12:16:40.000Z*
> According to the latest survey by FactSet, the median EPS estimate for Neurocrine Biosciences (NBIX-US) in 2026 has been

### [Neurocrine (NBIX) Gets a Buy from Stifel Nicolaus](https://longbridge.com/en/news/285372122.md)
*2026-05-06T11:46:02.000Z*
> In a recent report, Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Neurocrine (NBIX) with a price targe

### [Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia | NBIX Stock News](https://longbridge.com/en/news/285377822.md)
*2026-05-06T04:30:35.000Z*
> Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiatin

### [Neurocrine Biosciences Q1 Adjusted Earnings, Revenue Rise](https://longbridge.com/en/news/285262207.md)
*2026-05-05T20:15:00.000Z*
> 04:15 PM EDT, 05/05/2026 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) reported Q1 adjusted earnings late Tuesday of